Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders
Open Access
- 5 June 2026
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pharmacology and Therapeutics
- Vol. 17 (2) , 118616
Abstract
Gastroparesis, functional dyspepsia, chronic constipation, esophageal motility disorders, and colonic dysmotility are among the gastrointestinal (GI) motility disorders that constitute a significant global health burden. These disorders lead to reduced quality of life, higher healthcare utilization, and substantial socioeconomic costs. Therapeutic options are still scarce despite their prevalence. Prokinetic medications currently on the market offer only modest symptomatic relief, frequently reaching a plateau in efficacy, and their long-term use is limited by safety concerns, especially those related to cardiovascular and neurological side effects, as well as limited regional availability of some agents. The conceptual framework has moved beyond a purely neurocentric model due to recent advances in our understanding of GI motor physiology. The integrated functions of enteric neurobiology, gut-brain axis signaling, smooth muscle contractile pathways, interstitial cells of Cajal as motility pacemakers, and neuromodulatory circuits are highlighted by emerging mechanistic insights. These advancements have made it easier to find new pharmacologic targets and treatment approaches. An overview of new classes of prokinetic and motility-modulating drugs, such as selective receptor agonists and antagonists, hormone-based treatments, neuromodulators, and drugs that target pacemaker cell and smooth muscle function, is given in this review. Lastly, the clinical ramifications of these developing treatments are examined, with a focus on individualized treatment plans and potential future paths to enhance GI motility disorder efficacy, safety, and disease-specific management.Keywords
This publication has 66 references indexed in Scilit:
- Prevalence and clinical implications of duodenal eosinophilia in patients with refractory functional dyspepsia: A cross-sectional analysisIndian Journal of Gastroenterology, 2026
- The road to Rome IV and beyond: Evolution, refinements and future considerations for the Rome criteria for functional gastrointestinal disordersIndian Journal of Gastroenterology, 2025
- Overlap of ‘disorders of gut-brain interaction’ and their impact on quality of life and somatization in a tertiary care center- A cross-sectional studyIndian Journal of Gastroenterology, 2025
- Efficacy and safety of elobixibat in patients with chronic constipation—A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from IndiaIndian Journal of Gastroenterology, 2025
- Indian consensus on chronic constipation in adults: A joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of GastroenterologyIndian Journal of Gastroenterology, 2018
- Prokinetics in the Management of Functional Gastrointestinal DisordersCurrent Gastroenterology Reports, 2017
- Efficacy of mosapride citrate in proximal gastric accommodation and gastrointestinal motility in healthy volunteers: a double-blind placebo-controlled ultrasonographic studyJournal of Gastroenterology, 2010
- Drug‐Induced QT Interval Prolongation—Regulatory Guidance and Perspectives on hERG Channel Studies2005
- A clinical trial of bethanechol in patients with xerostomia after radiation therapyOral Surgery, Oral Medicine, Oral Pathology, 1994
- Erythromycin induces migrating motor complex in human gastrointestinal tractDigestive Diseases and Sciences, 1986